Second malignancies: Clinical relevance and basic research (review)

International Journal of Oncology

Volumn 9, Issue 4, 1996, Pages 763-776

  Munker, Reinhold ^a,b,d   Hiller, Erhard ^b   Melnyk, Anton ^a   Gutjahr, Peter ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

carcinogenesis; second malignancies

Indexed keywords

ADULT; AGED; ARTICLE; CHILD; CHILDHOOD CANCER; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SECOND CANCER;

EID: 0029791826     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (159)

1. Canellos GP, de Vita VT, Arseneau JC, et al: Second malignancies complicating Hodgkin's disease in remission. Lancet 1: 947-949, 1975.
2. Valagussa P, Santoro A, Fossati-Bellani F, et al: Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 6: 830-837, 1986.
3. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318: 76-81, 1988.
4. Sont JK, von Stiphout WAHJ, Noordijk EM, et al: Increased risk of second cancers in managing Hodgkin's disease: the 20-year Leiden experience. Ann Hematol 65: 213-218, 1992.
5. Rodriguez MA, Fuller LM, Zimmerman SO, et al: Hodgkin's disease: study of treatment intensities and incidence of second malignancies. Ann Oncol 4: 125-131, 1993.
6. Abrahamsen JF, Andersen A, Hannisdal E, et al: Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time and age. J Clin Oncol 11: 255-261, 1993.
7. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: a 20 year follow-up study. J Clin Oncol 12: 312-325, 1994.
8. Dietrich PY, Henry-Amar M, Cosset JM, et al: Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? Blood 84: 1209-1215, 1994.
9. Henry-Amar M on behalf of the IDHD: Second cancer after the treatment for Hodgkin's disease: a report from the international database on Hodgkin's disease. Ann Oncol 3 (Supp 4): 117-128, 1992.
10. Kaldor JM, Day NE, Clarke EA, et al: Leukemia following Hodgkin's disease. N Engl J Med 322: 7-13, 1990.
11. Devereux S, Selassie TG, Vaughan-Hudson G, et al: Leukemia complicating treatment for Hodgkin's disease: the experience of the British national lymphoma investigation. Br Med J 301: 1077-1080, 1990.
12. Andrieu JM, Ifrah N, Payen C, et al: Increased risk of secondary acute nonlymphocytic leukemia after extensive field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 8: 1148-1154, 1990.
13. Le Beau MM, Albain KS, Larson RA, et al: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 4: 325-345, 1986.
14. Johansson B, Mertens F, Hedim S, et al: Cytogenetics of secondary myelodysplasia and acute nonlymphocytic leukemia. Eur J Haematol 47: 17-27, 1991.
15. van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW, et al: Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12: 1063-1073, 1994.
16. Zarate-Osorno A, Medeiros LJ, Longo DL, et al: Non-Hodgkin's lymphomas arising in patients successfully treated for Hodgkin's disease. Am J Surg Pathol 16: 885-895, 1992.
17. List AF, Coll DC and Greco AF: Lung cancer in Hodgkin's disease: association with previous radiotherapy. J Clin Oncol 3: 215-221, 1985.
18. Kaldor JM, Day NE, Bell J, et al: Lung cancer following Hodgkin's disease: a case control study. Int J Cancer 52: 677-681, 1992.
19. Yahalom J, Petrek JA, Biddinger PW, et al: Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 10: 1674-1681, 1992.
20. Hancock SL, Tucker MA and Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85: 25-31, 1993.
21. Doria R, Holford T, Farber LR, et al: Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 13: 2016-2022, 1995.
22. Meadows AT, Obringer AC, Marrero O, et al: Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. Med Pediat Oncol 17: 477-484, 1989.
23. Tarbell NJ, Gelber RD, Weinstein HJ, et al: Sex differences in risk of second malignant tumors after Hodgkin's disease in childhood. Lancet 3411: 1428-1432, 1993.
24. Beaty O, Hudson MM, Greenwald C, et al: Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 113: 603-609, 1995.
25. Bhatia S, Robison LL, Oberlin O, et al: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334: 745-751, 1996.
26. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, et al: Risk of second primary cancer after Hodgkin's disease in patients in the British national lymphoma investigation: relationship to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer 68: 1006-1011, 1993.
27. Travis LB, Curtis RE, Hankey BF, et al: Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 84: 1422-1427, 1992.
28. Travis LB, Curtis RE, Glimelius, et al: Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 85: 1932-1937, 1993.
29. Travis LB, Curtis RE, Glimelius, et al: Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87: 524-530, 1995.
30. Kampmeier P, Spielberger R, Dickstein J, et al: Increased incidence of second neoplasms in patients treated with interferon α2b for hairy cell leukemia: a clinicopathologic assessment. Blood 83: 2931-2938, 1994.
31. Lowsky R, Lipton J, Fyles G, et al: Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 12: 2187-2192, 1994.
32. Witherspoon RP, Fisher LD, Schoch G, et al: Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 321: 784-789, 1989.
33. Stone RM, Neuberg D, Soiffer R, et al: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12: 2535-2542, 1994.
34. Miller JS, Arthur DC, Litz CE, et al: Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83: 3780-3786, 1994.
35. Li FP: Second malignant tumors after cancer in childhood. Cancer 40: 1899-1902, 1977.
36. Eng C, Li FP, Abramson DH, Ellsworth RM, et al: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85: 1121-1128, 1993.
37. Hawkins MM, Kinnier Wilson LM, Burton HS, et al: Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 88: 270-278, 1996.
38. Olsen JH, Garwicz S, Hertz H, et al: Second malignant neoplasms after cancer in childhood or adolescence. Br Med J 304: 951-958, 1992.
39. Gutjahr P: Sekundärmalignome nach Krebserkrankungen bei Kindern. Dtsch Ärztebl 90: 1593-1604, 1993.
40. Gutjahr P für die Arbeitsgruppe Zweitmalignome: Zweitmalignome nach Tumor-und Leukämiebehandlung im kindesalter. Dtsch Med Wochenschr 110: 1599-1606, 1985.
41. Hawkins MM, Draper GJ and Kingston JE: Incidence of second primary tumours among childhood cancer survivors. Br J Cancer 56: 339-347, 1987.
42. Miké V, Meadows AT and D'Angio GJ: Incidence of second malignant neoplasms in children: results of an international study. Lancet 2: 1326-1330, 1982.
43. Neglia JP, Meadows AT, Robison LL, et al: Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 325: 1330-1336, 1991.
44. Rosso P, Terracini B, Fears TR, et al: Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy. Int J Cancer 59: 451-456, 1994.
45. Ron E, Modan B, Boice JD Jr, et al: Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 319: 1033-1039, 1988.
46. Pui CH, Ribeiro RC, Hancock ML, et al: Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325: 1682-1687, 1991.
47. Hawkins MM, Kinnier Wilson LM, Stovall MA, et al: Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. Br Med J 304: 951-958, 1992.
48. Huvos AG and Woodard HQ: Postradiation sarcomas of bone. Health Phys 55: 631-636, 1988.
49. Robison LL: Survivors of childhood cancer and risk of a second tumor. J Natl Cancer Inst 85: 1102-1103, 1992.
50. Breslow NE, Takashima JR, Whitton JA, et al: Second malignant neoplasms following treatment for Wilms' tumor: a report from the national Wilms' tumor study group. J Clin Oncol 13: 1851-1859, 1995.
51. Heyn R, Haeberlen V, Newton WA, et al: Second malignant neoplasms in children treated for rhabdomyosarcoma. J Clin Oncol 11: 262-270, 1993.
52. Bokemeyer C and Schmoll HJ: Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 13: 283-292, 1995.
53. Boysen M and Loven JÖ: Second malignant neoplasms in patients with head and neck squamous carcinomas. Acta Oncol 32: 283-288, 1993.
54. Schwartz LH, Ozsahin M, Zhang GN, et al: Synchronous and metachronous head and neck carcinomas. Cancer 74: 1993-1998, 1994.
55. Boice JD, Day NE, Andersen A, et al: Second cancers following radiation treatment for cervical cancer: an international collaboration among cancer registries. J Natl Cancer Inst 74: 955-977, 1985.
56. Werner-Wasik M, Schmid CH, Bornstein LE, et al: Increased risk of second malignant neoplasms outside radiation fields in patients with cervical carcinoma. Cancer 75: 2281-2285, 1995.
57. Cuzick J, Erskine S, Edelman D, et al: A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer 55: 523-529, 1987.
58. Paccagnella A, Chiarion-Sileni V, Soesan M, et al: Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. Cancer 68: 975-980, 1991.
59. Lynch HT, Watson P, Smyrk TC, et al: Colon cancer genetics. Cancer 70: 1300-1312, 1992.
60. Cunningham C and Dunlop MG: Genetics of colorectal cancer. Br Med Bull 50: 640-655, 1994.
61. Aaltonen LA and Peltomäki P: Genes involved in hereditary nonpolyposis colorectal cancer. Anticancer Res 14: 1657-1660, 1994.
62. Stern HS: Contributions of molecular genetics .to the clinical management of colorectal cancer. Am J Surg 171: 10-15, 1996.
63. Boice JD, Greene MH, Killen JH, et al: Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 309: 1079-1083, 1983.
64. Eeles RA, Stratton MR, Goldar DE, et al: The genetics of familial breast cancer and their practical implications. Eur J Cancer 30A: 1383-1390, 1994.
65. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA-1. Science 266: 66-71, 1994.
66. Kent P, O'Donoghue JM, O'Honlon DM, et al: Linkage analysis and the susceptibility gene (BRCA-1) in familial breast cancer. Eur J Surg Oncol 21: 240-241, 1995.
67. Rosen PP, Liebermen PH, Braun DW, et al: Lobular carcinoma in situ of the breast. Am J Surg Pathol 2: 225-251, 1974.
68. Ciatto S, Catalioti L, Cardona G, et al: Risk of infiltrating breast cancer subsequent to lobular carcinoma in situ. Tumori 78: 244-246, 1992.
69. Carson W, Sanchez-Forgach E, Stomper P, et al: Lobular carcinoma in situ: observation without surgery as an appropriate therapy. Ann Surg Oncol 1: 141-146, 1994.
70. Lee JSY, Grant CS, Donohue JH, et al: Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 118: 640-648, 1995.
71. Kinnie DW, Petrek JA, Osborne MP, et al: Breast carcinoma in situ. Arch Surg 124: 33-36, 1989.
72. Silverstein MJ, Poller DN, Waisman JR, et al: Prognostic classification of breast ductal carcinoma-in situ. Lancet 345: 1154-1157, 1995.
73. Allred DC, O'Connell P, Fuqua SAW, et al: Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat 32: 13-18, 1994.
74. Ernster VL, Barclay J, Kerlikowske K, et al: Incidence of and treatment for ductal carcinoma in situ of the breast. J Am Med Assoc 275: 913-918, 1996.
75. Fisher B, Constantino J, Redmond C, et al: Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Eng J Med 328: 1581-1586, 1993.
76. Healy EA, Cook EF, Orav EJ, et al: Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 11: 1545-1552, 1993.
77. Early breast cancer panelist's collaborative group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85, 1992.
78. Love RR: Prevention of breast cancer in premenopausal women. Monographs-Natl Cancer Inst 16: 61-65, 1994.
79. Early breast cancer trialists' collaborative group: Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 333: 1444-1455, 1995.
80. Cuzick J, Stewart L, Rutquist J, et al: Cause specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12: 447-453, 1994.
81. Curtis RE, Boice JD, Stovall MPH, et al: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326: 1745-1751, 1992.
82. Curtis RE, Boice JD, Stovall M, et al: Leukemia risk following radiotherapy for breast cancer. J Clin Oncol 7: 21-29, 1989.
83. Fisher B, Rockette H, Fisher ER, et al: Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NASBP experience. J Clin Oncol 3: 1640-1658, 1985.
84. Valagussa P, Moliterni A, Terenziani M, et al: Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 5: 803-808, 1994.
85. Tallman MS, Gray R, Bennett JM, et al: Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern cooperative oncology group experience. J Clin Oncol 13: 1557-1563, 1995.
86. Inskip PD, Stovall M and Flannery JT: Lung cancer risk and radiation dose among women treated for breast cancer. J Natl Cancer Inst 86: 983-988, 1994.
87. Neugut AI, Murray T, Santos J, et al: Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer 73: 1615-1620, 1994.
88. Rutqvist LE, Johansson H, Signomklao T, et al: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87: 645-651, 1995.
89. Communication: NSABP halts B14 trial. J Natl Cancer Inst 87: 1829, 1995.
90. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the (NASBP) B-14. J Natl Cancer Inst 86: 527-537, 1994.
91. Gelber RD, Goldhirsch A and Coates AS: Adjuvant therapy for breast cancer: understanding the overview. J Clin Oncol 11: 580-585, 1993.
92. Martini N, Bains MS, Burt ME, et al: Incidence of local recurrence and second primary tumors in resected stage 1 lung cancer. J Thorac Cardiovasc Surg 109: 120-129, 1995.
93. Thomas PA and Rubinstein L: Malignant disease appearing late after operation for T1 N0 non-small cell lung cancer. The lung cancer study group. J Thorac Cardiovasc Surg 106: 1053-1058, 1993.
94. Salminen E, Pukkala E, Teppo L, et al: Risk of second cancers among lung cancer patients. Acta Oncol 34: 165-169, 1995.
95. Furuta M, Hayakawa K, Mitsuhashi N, et al: Second lung cancer following radiation therapy of locally advanced pulmonary cancer. Lung Cancer 10: 251-255, 1993.
96. Keller SM: Treatment of intrathoracic recurrent non-small cell lung cancer. Semin Oncol 20: 446-450, 1993.
97. Souhami RL and Law K: Longevity in small cell lung cancer: a report to the lung cancer subcommittee of the UK coordinating committee for cancer research. Br J Cancer 61: 584-589, 1989.
98. Lassen U, Osterlind K, Hansen M, et al: Long term survival in small cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1,714 consecutive patients. J Clin Oncol 13: 1215-1220, 1995.
99. Johnson BE, Grayson J, Makuch RW, et al: Ten year survival of patients with small cell lung cancer treated with combination chemotherapy with or without irradiation. J Clin Oncol 8: 396-401, 1990.
100. Sagman U, Lishner M, Maki E, et al: Second primary malignancies following diagnosis of small cell lung cancer. J Clin Oncol 10: 525-533, 1992.
101. Johnson BE, Linnoila I, Williams JP, et al: Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J Clin Oncol 13: 101-111, 1995.
102. Heyne KH, Lippman SM, Lee JJ, et al: The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol 10: 1519-1524, 1992.
103. Richardson GE, Tucker MA, Venzon DJ, et al: Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 119: 383-390, 1993.
104. Pastorino U: The problem of second cancers and the European experience with chemo-prevention. Lung Cancer 11 (suppl 3): 67-70, 1994.
105. Tockman MS, Erozan YS, Gupta P, et al: The early detection of second primary lung cancers by sputum immunostaining. Chest 106 (Suppl): 385-390, 1994.
106. Li FP, Fraumeni JF, Mulvihill JJ, et al: A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358-5362, 1988.
107. Birch JM: Li-Fraumeni syndrome. Eur J Cancer 30A: 1935-1941, 1994.
108. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1234-1238, 1990.
109. Cawthon RM, Weiss R, Xu G, et al: A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62: 193-201, 1990.
110. Easton DF: Cancer risks in A-T heterozygotes. Int J Radiat Biol 66: 177-182, 1994.
111. Savitsky K, Bar-Shira A, Gilad S, et al: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749-1753, 1995.
112. Eng C and Ponder BAJ: The role of gene mutations in the genesis of familial cancers. FASEB J 7: 910-919, 1993.
113. Hunger SP, Sklar J and Link MP: Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the literature. J Clin Oncol 10: 156-163, 1992.
114. Groupe Franç Cytogén Hématol: Acute leukemia treated with intensive chemotherapy in patients with a history of previous chemo- and/or radiotherapy: prognostic significance of karyotype and preceding myelodysplastic syndrome. Leukemia 8: 87-91, 1994.
115. De Witte T and Gratwohl A: Bone marrow transplantation for myelodysplastic syndrome and secondary leukaemias. Br J Haematol 84: 361-364, 1993.
116. Levine EG and Bloomfield CD: Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19: 47-84, 1992.
117. Kantarjian HM, Keating MJ, Walters RS, et al: Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol 4: 1748-1757, 1986.
118. Pedersen-Bjergaard J, Larson S, Struck J, et al: Risk of therapy-related leukemia and preleukemia after Hodgkin's disease: relation to age, cumulative dose of alkylating agents, and time frome chemotherapy. Lancet 2: 83-88, 1987.
119. Andersson M, Philip P and Pedersen-Bjergaard: High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. Cancer 65: 2460-2464, 1990.
120. Darrington DL, Vose JM, Anderson JR, et al: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12: 2527-2534, 1994.
121. Greene MH, Harris EL, Gershenson DM, et al: Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 105: 360-367, 1986.
122. Pui C, Behm F, Raimondi S, et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321: 136-142, 1989.
123. Winick NJ, McKenna RW, Shuster JJ, et al: Secondary acute myelogenous leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11: 209-217, 1993.
124. Cortes J, O'Brien S, Kantarjian H, et al: Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia 8: 2174-2178, 1994.
125. Pui CH, Relling MV, Rivera GK, et al: Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 9: 1990-1996, 1995.
126. Pedersen-Bjergaard J, Sigsgaard T, Nielsen D, et al: Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epidoxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 10: 1444-1451, 1992.
127. Sandoval C, Pui CH, Bowman LC, et al: Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 11: 1039-1045, 1993.
128. Sugita K, Furukawa T, Tsuchida M, et al: High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin's lymphoma. Amer J Pediat Hematol Oncol 15: 99-104, 1993.
129. Gu Y, Nakamura T, Alder H, et al: The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 71: 691-700, 1992.
130. Tkachuk DC, Kohler S and Cleary ML: Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemia. Cell 71: 691-700, 1992.
131. Felix CA, Hosler MR, Winick NJ, et al: ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 85: 3250-3256, 1995.
132. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86: 3542-3552, 1995.
133. Quesnel B, Kantarjian H, Pedersen-Bjergaard J, et al: Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 11: 2370-2379, 1993.
134. Rivera GK, Pui CH and Crist WM: The epipodophyllotoxins: both sides of the coin. J Clin Oncol 11: 1624-1625, 1993.
135. Malkin D, Jolly KW, Barbier N, et al: Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326: 1309-1315, 1992.
136. Hsu IC, Metcalf RA, Sun T, et al: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428, 1991.
137. Perera FP and Whyatt RM: Biomarkers and molecular epidemiology in mutation/cancer research. Mutat Res 313: 117-129, 1994.
138. Cox R: Molecular mechanisms of radiation oncogenesis. Int J Radiat Biol 65: 57-64, 1994.
139. Little JB: Cellular, molecular, and carcinogenic effects of radiation. Hematol Oncol Clin N Amer 7: 337-352, 1953.
140. De Benedetti VMG, Travis LB, Welsh JA, et al: p53 mutations in lung cancer following radiation therapy for Hodgkin's disease. Cancer Epidem Biomarker Prev 5: 93-98, 1996.
141. Sen P, Bailey NM, Hagemeister FB, et al: Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential. Cancer Res 50: 558-562, 1990.
142. White AD, Jones BM, Clark RE, et al: Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma. Carcinogenesis 13: 1095-1099, 1992.
143. Spitz MR, Hoque A, Trizna Z, et al: Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 86: 1681-1684, 1995.
144. Kleinerman RA, Littlefield LG, Tarone RE, et al: Chromosome aberrations in lymphocytes from women irradiated for benign and malignant gynecologic disease. Radiat Res 139: 40-46, 1994.
145. Liu Y, Hernandez AM, Shibata D, et al: BCL-2 translocation frequency rises with age in humans. Proc Natl Acad Sci USA 91: 8910-8914, 1994.
146. Mott MG, Boyse J, Hewitt M, et al: Do mutations at the glycophorin A locus in patients treated for childhood Hodgkin's disease predict secondary leukemia? Lancet 343: 828-829, 1994.
147. Kelsey KT, Caggana M, Mauch PM, et al: Mutagenesis after cancer therapy. Environ Health Perspect 101: 177-184, 1993.
148. Taylor C, McGlynn H, Carter G, et al: RAS and FMS mutations following cytotoxic therapy for childhood acute lymphoblastic leukaemia. Leukemia 9: 466-470, 1995.
149. Biernaux C, Loos M, Sels A, et al: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86: 3118-3122, 1995.
150. Traweek ST, Slovak ML, Nademanee AP, et al: Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 84: 957-963, 1994.
151. Giardini R, Martelli G, Rilke F, et al: Diagnostic problems of second primary malignancies detected by fine-needle aspiration cytology. Cancer 72: 2716-2722, 1993.
152. Lippman SM, Benner SE and Hong WK: Cancer chemoprevention. J Clin Oncol 12: 851-873, 1994.
153. Benner SE, Lippman SM and Hong WK: Retinoid chemoprevention of second primary tumors. Semin Hematol 31: 26-30, 1994.
154. Hong WK, Lippman SM, Hittelman WN, et al: Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin Cancer Res 1: 677-686, 1995.
155. Hong WK, Lippman SM, Itri LM, et al: Prevention of second malignant tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323: 795-801, 1990.
156. Benner SE, Pajak TF, Lippman SM, et al: Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 86: 140-141, 1994.
157. Pastorino U, Infante M, Maioli M, et al: Adjuvant treatment of stage I lung cancer with huigh-dose vitamin A. J Clin Oncol 11: 1216-1222, 1993.
158. Smith MA, Parkinson DR, Cheson BD, et al: Retinoids in cancer therapy. J Clin Oncol 10: 839-864, 1992.
159. Offit K and Brown K: Quantitating familial cancer risk: a resource for clinical oncologists. J Clin Oncol 12: 1724-1736, 1994.